High serum CCL18 predicts a poor prognosis in patients with laryngeal squamous cell carcinoma
| Autor: | Guo Li, Gangcai Zhu, Haolei Tan, Yuanzheng Qiu, Gang Wang, Donghai Huang, Yong Liu, Yuexiang Qin, Xiyu Chen, Yunyun Wang, Li She, Juncheng Wang, Diekuo Zhang, Zhe Shen, Ming Wei, Jie Chen, Xin Zhang, Pingqing Tan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
business.industry LSCC medicine.medical_treatment CCL18 Tumor-associated macrophage Prognosis medicine.disease Gastroenterology Primary tumor Cytokine Oncology Internal medicine Tumor associated Macrophage medicine Biomarker (medicine) Clinical significance Stage (cooking) business Survival analysis Research Paper |
| Zdroj: | Journal of Cancer |
| ISSN: | 1837-9664 |
| DOI: | 10.7150/jca.37515 |
| Popis: | CCL18 is a cytokine secreted by M2 type tumor associated macrophages, which frequently over-expressed in diverse human cancers. However, the clinical significance of serum CCL18 in patients with laryngeal squamous cell carcinoma (LSCC) remains unknown. In this study, serum CCL18 was initially quantified by enzyme-linked immunosorbent assay (ELISA) in 146 patients with LSCC, 25 patients with precancerous lesions and 72 healthy volunteers. In addition, the correlations between serum CCL18 and clinicopathological parameters were analyzed. Our data revealed that serum CCL18 was obviously increased in patients with LSCC. Moreover, serum CCL18 level was significantly associated with primary tumor site (Glottic vs Others), T classification (T1+T2 vs T3+T4), clinical stage (I+II vs III+IV) and lymph node metastasis (N0 vs N+). Survival analysis demonstrated that patients with high serum CCL18 displayed a shorter survival time than those in patients with low serum CCL18. Importantly, serum CCL18 level and clinical stage were independent prognostic factors in patients with LSCC. Taken together, serum CCL18 could be used as a promising biomarker in patients with LSCC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|